866-997-4948(US-Canada Toll Free)

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2013 in Pharmaceuticals

Published By :

GlobalData

Published Date : Mar 2013

Category :

Banking

No. of Pages : 72 Pages


Partnerships, Licensing, Investments and M&A Deals and Trends for February 2013 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for February 2013 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena. 
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the last six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5

2 Pharmaceuticals & Healthcare, Global, Deal Summary 7
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, February 2013 7
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, February 2013 9
2.2.1 Biogen Idec to Acquire Elans Interest in Multiple Sclerosis Drug Tysabri for $3.2 Billion 9
2.2.2 Cardinal Health to Acquire AssuraMed for Up to $2.07 Billion 10
2.2.3 Mylan to Acquire Agila Specialties from Strides Arcolab for Up to $1.85 Billion 10
2.2.4 Quintiles Transnational Files Registration Statement for IPO to Raise Up to $600 Million 10
2.2.5 Chiasma Enters into Licensing Agreement with Roche for Octreolin 11
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, February 2013 12
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, February 2013 13

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 14
3.1 Pharmaceuticals & Healthcare, Global, M&A, February 2013 14
3.1.1 Top M&A Deals in February 2013 15
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, September 2012February 2013 16
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 2013 17
3.2.1 Top Equity Offering Deals in February 2013 18
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, September 2012 February 2013 19
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 2013 20
3.3.1 Top PE/VC Deals in February 2013 21
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, February 2013 22
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, February 2013 23
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, September 2012 February 2013 25
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2012 February 2013 26

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2013 27
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2013 27
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2012 February 2013 28
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2013 29
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, February 2013 30
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2012 February 2013 31
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, September 2012 February 2013 32
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), September 2012 February 2013 33
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2012 February 2013 34

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2013 35
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2013 35
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2013 36
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, February 2013 37
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, February 2013 37
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 2013 38
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2012 February 2013 39
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2012 February 2013 40
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2012 February 2013 41
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2012 February 2013 43

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 44
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, February 2013 44
6.1.1 Oncology Deals of the Month 45
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 2013 47
6.2.1 Central Nervous System Deals of the Month 48
6.3 Pharmaceuticals & Healthcare, Global, Immunology Deals, February 2013 49
6.3.1 Immunology Deal of the Month 50
6.4 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 2013 51
6.4.1 Infectious Diseases Deals of the Month 52
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, February 2013 53
6.5.1 Metabolic Disorders Deal of the Month 54
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 2013 55
6.6.1 Cardiovascular Deal of the Month 56
6.7 Pharmaceuticals & Healthcare, Global, Respiratory, Deals, February 2013 57
6.7.1 Respiratory Deal of the Month 58

7 Deal Summary by Geography 59
7.1 Pharmaceuticals & Healthcare, North America Deals, February 2013 59
7.1.1 North America Deals of the Month 60
7.2 Pharmaceuticals & Healthcare, Europe, Deals, February 2013 62
7.2.1 Europe Deals of the Month 63
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 2013 65
7.3.1 Asia-Pacific Deals of the Month 66
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, February 2013 67
7.4.1 Rest of the World Deals of the Month 68

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 69
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2012 February 2013 69
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2012 February 2013 70

9 Further Information 71
9.1 Methodology 71
9.2 About GlobalData 71
9.3 Contact Us 72
9.4 Disclosure information 72
9.5 Disclaimer 72

List of Table


Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 8
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, February 2013 9
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), February 2013 13
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 15
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, February 2013 15
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2012 February 2013 16
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 17
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, February 2013 18
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 19
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 20
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, February 2013 21
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, September 2012 February 2013 22
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), February 2013 24
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2012 February 2013 25
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2012 February 2013 26
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2012 February 2013 27
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2012 February 2013 28
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2012 February 2013 29
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), February 2013 30
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2012 February 2013 31
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2012 February 2013 33
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), September 2012 February 2013 34
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 35
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), September 2012 February 2013 36
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, February 2013 37
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, February 2013 37
Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, February 2013 38
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2012 February 2013 39
Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), February 2013 40
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2012 February 2013 42
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2013 43
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 45
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 48
Table 34: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 49
Table 35: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 52
Table 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 54
Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 55
Table 38: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 57
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 60
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 63
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 66
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 67
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2012 February 2013 69
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2012 February 2013 70

List of Chart


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2012 February 2013 7
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), February 2013 12
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), February 2013 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), September 2012 February 2013 14
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2012 February 2013 16
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), September 2012 February 2013 17
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2012 February 2013 19
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), September 2012 February 2013 20
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2012 February 2013 22
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), February 2013 23
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), February 2013 24
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2012 February 2013 25
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2012 February 2013 27
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2012 February 2013 28
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2012 February 2013 29
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2012 February 2013 31
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2012 February 2013 32
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2012 February 2013 33
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2012 February 2013 34
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), September 2012 February 2013 35
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2012 February 2013 36
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2012 February 2013 39
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2012 February 2013 40
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, September 2012 February 2013 41
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), September 2012 February 2013 42
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), February 2013 43
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), September 2012 February 2013 44
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), September 2012 February 2013 47
Figure 29: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), September 2012 February 2013 49
Figure 30: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), September 2012 February 2013 51
Figure 31: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 53
Figure 32: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), September 2012 February 2013 55
Figure 33: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), September 2012 February 2013 57
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), September 2012 February 2013 59
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), September 2012 February 2013 62
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), September 2012 February 2013 65
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), September 2012 February 2013 67
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2012 February 2013 69
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2012 February 2013 70

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports